Drugs / Reveratinib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT05751733 Comparator | Feb 2023 → Jan 2026 overdue | gastrointestinal stromal tumor | Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reveratinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05751733 ↗ |